Related Experiment Videos
Abnormal cholesterol biosynthesis in the Smith-Lemli-Opitz syndrome
Journal of Lipid Research
|June 1, 1996
Summary
Smith-Lemli-Opitz syndrome results from a defect in cholesterol biosynthesis, leading to low cholesterol and toxic precursor buildup. Dietary cholesterol may help correct these biochemical issues and improve symptoms.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Smith-Lemli-Opitz syndrome (SLOS) is an inherited metabolic disorder.
- It stems from a deficiency in the enzyme 7-dehydrocholesterol-delta7-reductase.
- This enzyme is crucial for the final step in cholesterol biosynthesis.
Purpose of the Study:
- To elucidate the biochemical basis of Smith-Lemli-Opitz syndrome.
- To understand the consequences of impaired cholesterol synthesis.
- To explore potential therapeutic interventions for SLOS.
Main Methods:
- Enzyme activity assays to identify the defect in 7-dehydrocholesterol-delta7-reductase.
- Analysis of sterol levels (cholesterol, 7-dehydrocholesterol, and derivatives) in affected individuals.
- Assessment of tissue development and function in the context of cholesterol deficiency.
Main Results:
- A genetic defect in 7-dehydrocholesterol-delta7-reductase was identified as the cause of SLOS.
- Reduced cholesterol levels and accumulation of 7-dehydrocholesterol and related sterols were observed.
- Abnormal tissue development, particularly in the brain, was linked to cholesterol deprivation and sterol precursor accumulation.
Conclusions:
- SLOS is characterized by impaired cholesterol biosynthesis due to a specific enzyme defect.
- The resulting biochemical abnormalities lead to significant developmental and functional deficits.
- Dietary cholesterol supplementation shows potential for correcting metabolic defects and alleviating SLOS symptoms.